Dudediligence.

Innoviva, Inc

INVANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$89.5MSep ’24$91.8MDec ’24$88.6MMar ’25$100.3MJun ’25$107.8MSep ’25$114.6MDec ’25$98.0MMar ’26$119.6MJun ’26
Net income, by quarter
$1.2MSep ’24$20.3MDec ’24−$46.6MMar ’25$63.7MJun ’25$89.9MSep ’25$164.2MDec ’25$186.6MMar ’26−$83.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$391.9M$331.3M$310.5M$358.7M$411.3M
Gross profitnone on filenone on file$246.0M$296.2M$307.7M
Operating income$375.1Mnone on file$113.9M$166.9M$163.7M
Net income$368.8M$220.3M$179.7M$23.4M$271.2M
Operating cash flow$363.8M$201.7M$141.1M$188.7M$196.9M
Free cash flow$363.8M$201.7M$140.7M$188.4M$195.8M
Cash$201.5M$291.0M$193.5M$305.0M$550.9M
Debt$394.7M$540.4M$446.2M$448.3M$257.7M
Shares outstanding69.6M69.2M63.3M62.7M74.6M